Acute Lymphoblastic Leukemia
Conditions
Keywords
Acute Lymphoblastic Leukemia, Fertility preservation, Anti-Mullerian hormone
Brief summary
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.
Interventions
None listed
Sponsors
IRCCS Burlo Garofolo
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Female less than 18 years of age * Diagnosis of acute lymphoblastic leukemia * enrollment within the first month after diagnosis
Exclusion criteria
* Previous treatments with cytostatics drugs * ALL as a second malignancy * Syndromic patient or primary hypogonadism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of blood AMH levels before ALL treatment | Within one months from ALL diagnosis | AMH levels will be evaluated in peripheral blood |
| Evaluation of blood AMH levels after ALL treatment | 24 months after ALL diagnosis | AMH levels will be evaluated in peripheral blood |
Countries
Italy
Contacts
Primary ContactNagua Giurici, MD
Outcome results
None listed